Predict your next investment

Aquinnah Pharmaceuticals company logo
HEALTHCARE | Drug Development
aquinnahpharma.com

See what CB Insights has to offer

Founded Year

2014

Stage

Loan | Alive

Total Raised

$16M

Last Raised

$250K | 1 yr ago

About Aquinnah Pharmaceuticals

Aquinnah Pharmaceuticals is a privately held biotechnology company focused on RNA binding proteins to slow the progression of ALS and other neurodegenerative diseases.

Aquinnah Pharmaceuticals Headquarter Location

Lab Central 700 Main Street

Cambridge, Massachusetts, 02139,

United States

617-863-3678

Latest Aquinnah Pharmaceuticals News

Aquinnah Pharmaceuticals Receives $750,000 Grant from the Alzheimer's Association and Tau Consortium...

Jan 17, 2019

News provided by Share this article CAMBRIDGE, Mass., Jan. 17, 2019 /PRNewswire/ -- Aquinnah Pharmaceuticals, leaders in stress granule biology that afflict a wide range of neurodegenerative disorders, announced today that it has been awarded $750,000 from the Tau Pipeline Enabling Program (T-PEP) to advance its drug development programs in tauopathy diseases, including Progressive Supranuclear Palsy, Alzheimer's Disease, and Fronto-temporal Dementia. T-PEP is a partnership between the Alzheimer's Association and the Tau Consortium ; a program of the Rainwater Charitable Foundation to explore new ways to prevent, reduce or remove pathological tau from the brain. Aquinnah Pharmaceuticals is the only company recipient and one of 5 awardees selected from 125 applications, to receive funding from the $3 million grant. Glenn Larsen, Ph.D., President and CEO of Aquinnah said, "Pioneering work from Aquinnah's co-founder Dr. Ben Wolozin, has shown that stress granule modulation in the brain represents a new and promising approach towards reducing effects of the toxic protein, tau, by showing improved lifespan and preservation of neurons and memory in mice, with potential application to a wide range of neurodegenerative diseases. Aquinnah has developed neuronal models that replicate human tau stress granule pathology and with this funding, we are screening chemical libraries containing over 250,000 small molecules, to identify molecules that have the potential to be developed as novel drugs. We are very pleased that the reviewers at the Alzheimer's Foundation and Tau Consortium recognize the work we are doing to bring hope to the millions of people affected by these grave disorders." Aquinnah's unique small molecule approach to the inhibition of tau pathology is through the stress granule protein TIA-1 pathway, where a 33% increase in mouse survival was observed, comparable to ~15 years of human life extension, and the best results ever reported in this human tauopathy model of Alzheimer's Disease. About Aquinnah Pharmaceuticals Aquinnah Pharmaceuticals is harnessing the power of stress granule biology to develop oral small molecule drug candidates in Neurodegenerative Orphan Diseases to prevent TDP-43 disease in amyotrophic lateral sclerosis (ALS); and tau disease pathology in Progressive Supranuclear Palsy, and other diseases including Alzheimer's disease; by developing inhibitors of stress granule pathology. Aquinnah is financially backed by Pfizer, Inc., AbbVie, Inc. and Takeda Pharmaceuticals. www.aquinnahpharma.com SOURCE Aquinnah Pharmaceuticals

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Aquinnah Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Aquinnah Pharmaceuticals is included in 3 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

N

Neuroscience

2,144 items

Companies developing products that monitor, analyze, protect, or otherwise influence the structure/function of the nervous system.

B

Biopharmaceuticals

5,732 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Aquinnah Pharmaceuticals Patents

Aquinnah Pharmaceuticals has filed 7 patents.

The 3 most popular patent topics include:

  • Neurological disorders
  • Rare diseases
  • Inflammations
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/21/2012

6/7/2016

Neurological disorders, Rare diseases, Inflammations, Proteins, Neurodegenerative disorders

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

5/21/2012

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

6/7/2016

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Neurological disorders, Rare diseases, Inflammations, Proteins, Neurodegenerative disorders

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Aquinnah Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Aquinnah Pharmaceuticals Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.